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Abstract
Background: Asthma pathogenesis and susceptibility involves a complex interplay between
genetic and environmental factors. Their interaction modulates the airway inflammation and
remodelling processes that are present even in mild asthma and governs the appearance and
severity of symptoms of airway hyperresponsiveness. While asthma is felt to develop as the result
of interaction among many different genes and signalling pathways, only a few genes have been
linked to an increased risk of developing this condition.
Results: We report the results of expression microarray studies using tissue obtained from
bronchial biopsies of healthy controls and of subjects with allergic asthma, both before and
following inhaled corticotherapy. We identified 79 genes that show significant differences in
expression (following Bonferroni cutoff using p < 6.6 × 10-6 to correct for multiple testing) in
asthmatics compared to controls at significance levels. These included 21 genes previously
implicated in asthma, such as NOS2A and GPX3, as well as new potential candidates, such as
ALOX15, CTSC and CX3CR1. The expression levels of one third of these transcripts were
partially or completely corrected following inhaled corticosteroid therapy.
Conclusion: The study shows that bronchial biopsies obtained from healthy and asthmatic
subjects display distinct expression profiles. These differences provide a global view of
physiopathologic processes active in the asthmatic lung and may provide invaluable help to clarify
the natural history of asthma.
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Asthma is a heterogeneous disease with variable clinical
presentations. Genetic and environmental factors likely
play a significant role in its pathogenesis, by modulating
the airway inflammation and remodeling processes.
Asthma airway inflammation and remodeling are charac-
terized by lymphocyte and eosinophil infiltration of the
bronchial mucosa and are accompanied by structural
changes including epithelial desquamation, subepithelial
fibrosis, mucus gland hyperplasia, modification of the
extracellular matrix and hypertrophy/hyperplasia of
smooth muscle cells [1,2]. Both processes involve inflam-
matory and structural cells and likely play an important
part in determining the development, chronicity and
severity of asthma in individual patients.
Despite many association and linkage studies, most
asthma-related genetic susceptibility factors and subphe-
notypes have yet to be established. With previous technol-
ogies, few candidate genes have been identified and
confirmed in different populations. These difficulties
highlight the importance of combining various
approaches to increase our knowledge on the many path-
ways that are affected during the pathogenesis of asthma
and possibly increase the likelihood of identifying
asthma-related genes harboring sequence variants that
predispose or modulate asthma and atopy. Large-scale
gene expression profiling with microarrays provide
opportunities to investigate a large number of genes that
may be implicated in the physiopathological processes
occurring in asthma. Within the last two years, several
studies have reported results of microarray experiments
comparing peripheral blood cells of asthmatic and allergic
subjects as well as lung tissue obtained from animal mod-
els or allergic airways disease [3-11]. For instance, in com-
parison to control subjects, peripheral blood cells of
asthmatics demonstrated modified expression of a variety
of cytokines (including IL-6, IL-8, IL-10, IL-12, IFN-γ, IFN-
α), [4,5]. Another study, demonstrated different gene
expression profiles including increased expression of
STAT6, IL-4, IL-13 in allergen-stimulated Th2 cells [6].
Treatment of peripheral eosinophils with IL-5 upregu-
lated 73 genes; of these genes, many known to play a role
in adhesion, migration or activation of eosinophils [7]. In
a monkey model of allergic asthma, cluster analysis of
microarray data revealed five groups of genes with unique
expression patterns [10,11]. One group included genes for
several chemokines (eotaxin, MCP-1, MCP-3, etc.) as well
as genes involved in tissue remodeling and antioxidant
responses [10,11]. Recently, Zimmermann and coworkers
have described a pathway involving arginine metabolism
in the context of allergic inflammation in mouse models
studied using expression microarrays [3]. Such gene
expression profile studies have demonstrated the useful-
ness of microarray technology to broadly characterize a
number of processes implicated in asthma.
Given that bronchial tissues are a primary site for airway
inflammation and remodeling in asthmatic subjects [12],
we selected this tissue to characterize gene expression pat-
terns in order to identify genes implicated in the patho-
genesis of asthma and possibly suggest novel
susceptibility genes. We also compared gene expression
profiles from bronchial tissues obtained from asthmatic
subjects before and following treatment with inhaled cor-
ticosteroids (ICS). These studies identified 79 genes of
known function that are differently expressed in asthmat-
ics compared to control subjects. Twenty-two genes have
an association with asthma reported in at least one publi-
cation (although many of these have not been replicated),
and 18 have a biological relevance in asthma pathophysi-
ology. ICS treatment partially or completely corrected the
expression of 26 of these genes (33%).
Results
Reproducibility of mRNA expression profiles
We optimized RNA extraction methods from bronchial
biopsies, which led to the routine generation of high-
quality RNA from each new set of tissues and allowed col-
lection of >5 µg of total RNA from a pool of 8 bronchial
biopsy cores. The variability of expression profiles in
bronchial biopsies was assessed by comparing expression
profiles obtained from control subjects to each other (fig-
ure 1A, r2 = 0.94 and data not shown). The high inter-indi-
vidual correlation among control samples demonstrates
that a pool of 8 bronchial biopsy cores provides a repro-
ducible sample of the large airways, and that gene expres-
sion measurements are similar in control subjects. In
contrast, comparisons of mean gene expression in asth-
matic and control groups (Figure 1B) as well as between
individual asthmatic and control patients (Figures 1C to
1F) reflect significant differences between these study
groups. Compared to figure 1A, the smaller correlation
coefficients observed in these comparisons (average r2 =
0.81 for individual patients) demonstrate the greater vari-
ability of gene expression between the two groups than
among control subjects.
Identification of differentially regulated transcripts in 
asthmatic and control patients
Of the 12,000 oligonucleotide probe pair sets contained
on the U95Av2 chip used in this study, 5,800 probe sets
were reliably detected in all bronchial biopsy pools
obtained from asthmatic and control subjects (raw data
presented in Table 1 [see Additional file 1]). 79 genes (92
transcripts) had significantly different expression levels
(Bonferroni cutoff was p < 6.6 × 10-6, corresponding to a
single test p < 0.05) between the control and asthmatic
groups; 74 of these 79 genes were grouped in 12Page 2 of 10
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BMC Genomics 2004, 5 http://www.biomedcentral.com/1471-2164/5/21Expression levels were measured for each of 12,000 genes on the Affymetrix U95Av2 GeneChipFigure 1
Expression levels were measured for each of 12,000 genes on the Affymetrix U95Av2 GeneChip. Expression levels are shown 
for 5800 genes that were detected in the biopsies used in this study. A. Scatter diagrams comparing the RNA expression pro-
files obtained from two control women (r2 = 0.94). B. Scatter diagram showing mean RNA expression profiles for asthmatic 
and control subjects (r2 = 0.80). The mean expression levels for NOS2A and CX3CR1, two genes that are differentially 
expressed between the two groups, are indicated (see also Table 1 [see Additional file 1]). C to F. Scatter diagrams comparing 
the RNA expression profile obtained from a normal female to expression profiles obtained from each female asthmatic subject.
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additional thirteen transcripts, including genes and ESTs,
were differentially expressed but could not be functionally
classified. Of the genes that were either up- (20) or down-
(54) regulated in asthmatic compared to control subjects,
13 were related to immune signaling molecules, 8 to
extracellular proteins, 9 to immune response, 9 to intrac-
ellular signaling component pathways, 8 to proteolytic
enzymes and 5 to transmembrane proteins. Other genes
were notably related to cell growth and proliferation (5),
cell adhesion (2), gene transcription (5) and free radical
metabolism (4). Many of these 74 identified genes are
already known to be modified in asthma i.e. NOS2A,
GPX3, TCRα and several proteolytic enzymes, but others
are newly implicated in asthma pathogenesis such as
ALOX15, CTSC, and CX3CR1.
Effects of inhaled corticosteroid treatment
According to the Chronolog recordings, the asthmatics
took respectively 24, 41, 48 and 50 ICS puffs of acceptable
quality over the 28 day-treatment period. This treatment
induced many changes in gene expression in the four asth-
matics, normalizing the expression of 21 genes whose
expression was modified in asthma compared to control
including NOS2A (Figure 2). Indeed, the comparison of
post-ICS asthmatic and control subjects' data showed sim-
ilar expression of these 21 genes (data not shown). How-
ever, ICS treatment further decreased the expression of 4
genes whose expression was already decreased in asthma
(Table 1 [see Additional file 1]). Fifty-two genes were not
modified by ICS treatment as shown for CX3CR1 in figure
2B. Furthermore, the comparison of asthmatic subjects
pre- and post-ICS treatment revealed a difference of
expression for 128 genes [see Additional file 1]. The tran-
scriptional response to ICS treatment differs significantly
for different functional classes of proteins (Figure 3). As
discussed above, asthmatic subjects overexpress several
proteolytic enzymes in comparison to control subjects:
ICS therapy effectively returns the expression of these
genes to baseline values (Figure 3A). Similarly, asthma-
associated changes in expression of genes involved in
immune signalling as well as extracellular proteins are
reversed in some cases (Figure 3B,3C). In contrast, ICS
have variable effects on the changes in expression of genes
implicated in intracellular signalling pathways: in some
cases, asthma-associated changes in gene expression are
augmented by ICS therapy (Figure 3D). Of interest, many
of the differences in gene expression seen between ICS-
treated asthmatic and control patients have been previ-
ously described in mouse models of allergic airways dis-
ease [3].
Discussion
This is the first global expression study of bronchial tissue
that allows the characterization of asthmatic airway phe-
notypes in comparison with normal gene expression pat-
tern. The data illustrate that microarray studies to detect
differentially regulated genes in bronchial biopsies of
asthmatic patients identify genes known to be modulated
in asthma and following corticosteroid therapy. These
genes may provide an excellent set of candidates to further
explore the biologic pathways involved in asthma suscep-
tibility and to better understand the true impact of first-
line therapy offered to asthmatic subjects following ATS
and Canadian recommendations [13].
Because of practical issues related to recruitment of sub-
jects for bronchoscopy, this study includes a modest
number of subjects and unequal numbers of men and
women in each group. There is no firm standard as regards
the optimal number of replicates required for any expres-
sion study. This number depends on the source of the
RNA material (heterogeneity versus homogeneity of tissue
sources) or on the intrinsic properties of each gene on the
array (copy number, amplitude of baseline fluctuations)
[14]. Four replicates for each biological state were
included in each group. The reproducibility of gene
expression in each group demonstrates a correlation sim-
ilar to results obtained by Novak et al. [14] when compar-
ing tissues in two mice from the same litter [14]. Paired
bronchoscopy, paired RNA extraction and microarray
analysis, and stringent statistical analyses developed for
microarrays were also used to improve the strength of the
comparison.
Application of this technology for studying gene expres-
sion profiles from bronchial biopsy samples may also be
limited by differences in cellular composition due to
differing proportions of epithelial cells, fibroblasts, and
smooth muscle cells that may occur in asthmatic and con-
trol tissue as a result of biopsy techniques. Indeed, less
epithelium has been observed on asthmatic broncho-
scope bronchial biopsies [15], and the biopsy technique
may sample deeper in the control bronchial mucosa as it
has no edema, no inflammatory infiltrate, and neither
mucous gland nor smooth muscle hyperplasia. Conse-
quently, it is impossible to ensure, even in the most care-
fully executed experiments, that samples originating from
the exact same tissue will bear the same cellular composi-
tion. RNA samples obtained from bronchial tissues will
reflect differences in relative amounts of different cell type
compositions. The expression levels of certain transcripts,
including RANTES, aggrecan, collagen type 11, and fibro-
modulin, may reflect smaller amounts of epithelium and
greater amounts of cartilage in biopsy specimens of con-
trol subjects compared to those of asthmatics. Other gene
expression discrepancies may also be due to cell prolifera-
tion and recruitment in bronchial mucosa as part of the
pathogenesis of asthma.Page 4 of 10
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limited by the disease's spatial and temporal heterogene-
ity. In asthma, the airway mucosal inflammatory/remod-
elling process is diffuse, thus reducing such possibility in
the present study. Moreover, although certain features –
such as the degree of eosinophil infiltratation – are more
intense in small airways [12], airway inflammation is not
a patchy disease, even in very mild asthma [16]. In our
previous experiments, inflammatory and remodelling fea-
tures were present in each biopsy obtained from asthmatic
subjects. Since physiopathological alterations are uni-
formly spread throughout the airways [12], we can there-
fore assume that random biopsies are fairly representative
of the entire lung. Asthma is a chronic disease, and
inflammatory and remodelling features remain quite sim-
ilar in stable disease [17].
After using stringent tests for determining significance
(see Methods), a very small fraction of the 5,800 tran-
scripts detected in bronchial biopsies showed differences
in expression levels between the control and asthmatic
groups. Since this study shows significant modifications
with a small number of subjects, the 74 identified genes
likely include those with the most persistent and possibly
the greatest alterations. Interestingly, the list of modified
genes included more genes with decreased as opposed to
increased expression. Moreover, our study has identified
overexpression of rather few genes coding for inflamma-
tory mediators in asthmatic subjects. However, the inclu-
sion of more subjects in each group will increase the
statistical power and, consequently, the number of signif-
icantly modified genes and very likely the number of
modified inflammatory genes.
NOS2A (A) and CX3CR1 (B) expression measured in the four analysed asthmatic samplesFigure 2
NOS2A (A) and CX3CR1 (B) expression measured in the four analysed asthmatic samples. At baseline (pre-ICS), the expres-
sion of NOS2A is increased but the expression of CX3CR1 is decreased. ICS treatment normalizes asthmatics' expression of 
NOS2A but does not modify CX3CR1 levels.
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Transcriptional response to ICS treatment. The transcriptional response to ICS differs significantly for different functional 
classes of proteins. Asthmatic patients overexpress several proteolytic enzymes in comparison to control subjects (D): ICS 
treatment returns the expression of these genes to baseline values. Asthma-associated changes in gene expression involved in 
immune signaling (A) as well as extracellular proteins (B) are reversed in some cases. ICS treatment has variable effect on the 
changes in expression of genes implicated in intracellular signaling pathways (C); in some cases, asthma-associated changes in 
gene expression are augmented by ICS therapy.
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ing nitric oxide synthase 2A [18-21], CD14 antigen [22],
T cell receptor alpha locus [23], small inducible cytokine
A5 (RANTES) [24], mucin [25,26], tryptases [27,28],
cathepsin C [29], and possibly glutathione peroxidase 3
[30], spleen tyrosine kinase [31], and also cathepsin G
[32], a serine protease, matches previously published
results and confirms the implication of candidate genes
already associated with asthma in previous studies. On
the other hand, the expression level of other genes is lower
in bronchial tissues of asthmatic subjects. The lower glu-
tathione peroxidase, an important antioxidant enzyme, in
tissues of asthmatic subjects confirms observations of
Misso et al., who reported a reduction in the activity of
glutathione peroxidase in asthma [33].
The fractalkine receptor (CX3CR1) showed expression
levels that are increased by two-fold in bronchial tissues of
subjects with normal pulmonary function in comparison
with asthmatic subjects. Fractalkine is a membrane-
bound chemokine expressed by endothelial cells of lungs
and is possibly involved in asthma pathogenesis [34].
Although there are limited data available on the fractalk-
ine receptor's role, some studies reveal that fractalkine is
pro-Th1, which could explain its higher expression level
among normo-reactive subjects. The SCYA21 gene codes
for the secondary lymphoid-tissue (SLC) chemokine that,
similarly to fractalkine, is chemotactic for lymphocytes
[35]. These and other genes, such as glypican 3 and fibulin
1, may also be important in asthma pathogenesis and
need to be validated by association studies, in situ hybrid-
ization and immunohistochemistry.
Another objective of this study was to evaluate the effect
of corticosteroid therapy on the expression level of genes,
more specifically on genes differentially expressed among
control and asthmatic subjects. This objective was based
on the hypothesis that expression disparities observed in
bronchial tissues of asthmatic subjects vs. healthy subjects
are mainly due to asthma physiopathology, and that
genes whose expression is modulated (up-regulated or
down-regulated) following therapy are involved in ICS
action mechanisms. The cumulative number of flutica-
sone 250 µg puffs in each subject, even the less compliant
one, over the 28-day treatment, likely reached the dose
required for near optimal ICS effects on inflammatory/
remodeling processes present in the bronchi of subjects
with mild asthma [36]. ICS had variable effects on gene
expression. They normalized some genes, including
NOS2A as previously reported [20]. The reasons for ICS-
induced decreases in T cell receptor beta locus and TYRO
protein tyrosine kinase binding protein remain unde-
fined. Most asthma-related genes seen in the asthma-to-
control comparisons (70%) remained unchanged after
therapy. Since ICS do not heal asthma, it is possible that
some of these genes are responsible for asthma chronicity.
Undeniably, the results obtained using microarrays need
to be validated with other techniques (for example in situ
hybridization and immunohistochemistry should permit
a better definition of specific cell types implicated in dif-
ferences in gene expression). Nevertheless, this study
shows that bronchial biopsies obtained from healthy and
asthmatic subjects display distinct expression profiles.
These differences provide a global view of physiopatho-
logic processes active in the asthmatic lung and may pro-
vide invaluable help to clarify the natural history of
asthma. Similar strategies may be extended to other
asthma phenotypes, such as more severe asthma, that are
associated with the highest morbidity and mortality. It
may allow us to define changes in expression of genes of
particular pathophysiologic or therapeutic interest, which
in turn may lead to more appropriate therapeutic inter-
ventions for patients.
Methods
Subject selection and characteristics
Four healthy subjects (2 men and 2 women) without a
history of allergy or asthma and four asthmatics (all
women) meeting the criteria of the American Thoracic
Society for the diagnosis of asthma were recruited to the
study [13]. The inclusion criteria included a stable treat-
ment for more than 3 months, no ICS therapy for at least
3 months preceding the study, no use of other drugs, and
no disease other than asthma. All subjects were non-
smokers and had not had respiratory infection within the
last 2 months. Forced expiratory volume in one second
(FEV1) values and the dose of methacholine that resulted
in a 20% fall in FEV1, corresponding to the PC20, were
measured in the morning, at least 8 h after any β2-agonist
inhalation. Control subjects had normal PC20 metha-
choline (≥16 mg/ml), negative skin prick tests, no known
systemic disease and took no medications. Asthmatic sub-
jects had PC20 < 8 mg/ml, a morning prebronchodilator
FEV1 ≥ 85% of the predicted value and required only a
short acting β2-agonist on demand less than 4 times a
week. In addition, all asthmatics had atopy symptoms
and positive prick skin tests. The patient characteristics are
summarized in Table 1: all had mild asthma according to
criteria of the Canadian Asthma Consensus Report [36].
The four asthmatic subjects agreed to take fluticasone
MDI 250 µg (Flovent®) with an aero-spacer, one puff twice
a day for a period of 28 days, and to have a second bron-
choscopy with bronchial biopsies at the end of the treat-
ment. The compliance of the subjects to ICS was evaluated
with a Chronolog (Medtrac) that registered time of MDI
actuation and quality of inhalation. The post-treatment
bronchoscopy was performed between 1 and 6 months
after the initial study. Approval for the study was obtainedPage 7 of 10
(page number not for citation purposes)
BMC Genomics 2004, 5 http://www.biomedcentral.com/1471-2164/5/21from ethics committee at Laval Hospital. All subjects pro-
vided informed consent.
Bronchoscopy, bronchial biopsy and RNA extraction
Bronchoscopies and bronchial biopsies were performed
for paired control and asthmatic subjects on the same
morning. After local anesthesia was provided using 2%
and 4% xylocaine, the flexible fiberoptic bronchoscope
(Olympus P200) was introduced into the bronchial tree.
Eight biopsies evaluated as acceptable by the research
assistant were taken from bronchi of the right lung using
alligator forceps (Olympus FB-15C-1). Biopsies were
obtained from the sub-segmental and segmental bron-
chial carinae of the lower (3–5 biopsies) and upper (1–2
biopsies) lobes, as well as the lobar carinae of the middle
(2 biopsies) and upper (1–2 biopsies) lobes to provide
adequate samples of the large airways (3rd to 5th bronchial
generation). When bronchoscopy was repeated after ICS
treatment, biopsies were taken from the left lung at simi-
lar bronchial levels. Bronchoscopies were performed
under oxygen at 2–3 l/minute by nasal catheter. Vital
signs, electrocardiograph output and oximetry were
recorded throughout the procedure. The biopsies were
processed and RNAs extracted in parallel the same day.
The tissue samples were immediately placed in RNAlater
(Ambion) to stabilize intracellular RNA during transport.
The samples were mechanically homogenized (Rotor/Sta-
tor homogeniser, PowerGen) and total RNA was extracted
using the RNEasy kit (Qiagen) according to the manufac-
turer's instructions. RNA integrity and yield was assessed
using Agilent BioAnalyser RNA LabChips® and by
spectrophotometry.
Microarray studies and analysis
Microarray expression studies were performed using
Affymetrix HG-U95Av2 GeneChips (Affymetrix, Santa
Clara, CA). These arrays contain 12,000 probe sets derived
from sequence clusters contained in Build 95 of Unigene,
which represent approximately 9,200 unique Unigene
sequence clusters including 6,000 functionally annotated
genes as well as expressed sequence tags (ESTs). To mini-
mize technical variability, RNA processing steps (RNA
extraction, probe labelling and chip hybridization) were
performed in parallel for control and asthmatic samples.
Probes for microarray analysis were prepared using 5 µg of
total RNA. A single expression array was hybridized for
each RNA sample. Following washing, the specifically
bound probe was detected by incubating the arrays with
SAPE (streptavidin phycoerthryin, Molecular Probes) and
scanning the chips using a Gene Array Scanner (Agilent).
The scanned images were analyzed using the Microarray
Analysis Suite 5.0 (MAS5, Affymetrix). Detailed probe
synthesis hybridization and washing protocols have been
previously described [14]. In total, biopsies from four
patients were obtained in each sample group (control,
asthmatic pre-ICS and asthmatic post-ICS). Data was
extracted using MAS5 and filtered to exclude genes that
were not expressed (taken to be equivalent to a MAS5
absent call) in all samples. The ArrayStat microarray anal-
ysis package (Imaging Research Inc., St. Catharines,
Ontario) was used to identify significant differences in
gene expression by performing pairwise comparisons of
microarray results obtained for each subject group. Array-
Stat estimates variance in gene expression using a local
pooled error model and implements the Bonferroni cor-
Table 2: Characteristics of subjects
Control subjects
Age Sex FVC* 1(%) FEV1* 1(%) PC20 mg/ml † Allergy‡
(1) 21 F 3.33 (97) 2.73 (91) 70.9 None
(2) 20 M 6.02 (107) 5.10 (105) >128 None
(3) 20 M 5.52 (98) 4.43 (101) 53.3 None
(4) 29 F 2.84 (80) 2.59 (86) 61.1 None
Asthmatic subjects
(1) 21 F 3.60 (91) 3.25 (96) 6.12 C, D, DPt, Du, G, Rw, T
(2) 20 F 3.50 (99) 2.80 (90) 2.53 C, D, DPt, G, Du, Rw, T
(3) 23 F 3.84 (100) 3.07 (96) 1.01 C, D, G, DPt, T
(4) 39 F 3.96 (112) 3.21 (110) 2.23 C, Du, G, Rw, T
* Forced vital capacity (FVC) and pre-bronchodilator forced expiratory volume in one second (FEV1) expressed in liter and (%) of predicted. † 
Concentration of methacholine inducing a 20% fall in FEV1. ‡ Skin response read at 10 min if mean wheal diameter ≥ 3 mm; C: cat, D: dog, DPt: D. 
Pteronyssinus, Du: dust, G: grass pollens, M: mold, Rw: ragweed, T: tree pollens. A wheal response to histamine ≥ 3 mm served as a positive 
control.Page 8 of 10
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performed using the Gene Microarray Pathway Profiler
(GenMAPP) [37]. The raw data is available from the NCBI
Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/
geo/.
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